<SEC-DOCUMENT>0001193125-19-137074.txt : 20190503
<SEC-HEADER>0001193125-19-137074.hdr.sgml : 20190503
<ACCEPTANCE-DATETIME>20190503171023
ACCESSION NUMBER:		0001193125-19-137074
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20190503
DATE AS OF CHANGE:		20190503
EFFECTIVENESS DATE:		20190503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231220
		FILM NUMBER:		19797179

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>d719612ds3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML><HEAD>
<TITLE>S-3ASR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on May 3, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">06-1376651</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92130 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">(858)&nbsp;558-2871</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
Registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephen R.
Davis </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(858)&nbsp;558-2871</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Austin&nbsp;D. Kim</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>L.&nbsp;Kay&nbsp;Chandler, Esq.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Executive&nbsp;Vice&nbsp;President,&nbsp;General&nbsp;Counsel&nbsp;and&nbsp;Secretary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Sean M. Clayton, Esq.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>ACADIA Pharmaceuticals Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cooley LLP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>4401 Eastgate Mall</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>San Diego, CA 92130</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>San Diego, CA 92121-1909</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">558-2871</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">From time to time after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box:&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form
is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box:&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a
smaller reporting company. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;to&nbsp;be<BR>Registered&nbsp;(1)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum<BR>Offering&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per&nbsp;Share&nbsp;(3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum<BR>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price&nbsp;(3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.0001 par value</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">40,203,111</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$24.11</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$969,297,006</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$117,479</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes 489,269 shares of common stock that may be issued upon the exercise of warrants. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act, the shares being registered hereunder include such indeterminate
number of additional shares of common stock as may be issuable as a result of stock splits, stock dividends or similar transactions with respect to the shares being registered hereunder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under
the Securities Act, based upon the average of the high and low prices for the common stock on May&nbsp;1, 2019, as reported by the Nasdaq Global Select Market. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g719612g97y90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the
disposition from time to time of up to 40,203,111 shares of our common stock, which includes 489,269 shares of our common stock issuable upon the exercise of warrants, which are held by the selling stockholders named in this prospectus<I>. </I>We
are not selling any common stock under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders. We will, however, receive the net proceeds of any warrants exercised for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell the shares of common stock described in this prospectus in a number of different ways and at varying prices. We provide more
information about how the selling stockholders may sell their shares of common stock in the section entitled &#147;Plan of Distribution&#148; on page 9. The selling stockholders will bear all commissions and discounts, if any, attributable to the
sale or disposition of the shares, or interests therein. We will bear all costs, expenses and fees in connection with the registration of the shares. We will not be paying any underwriting discounts or commissions in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;ACAD&#148;. On May 2, 2019, the last reported sale price of our common
stock was $25.50 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>An investment in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties referred to under the heading
&#147;<A HREF="#rom719612_2">Risk Factors</A>&#148; beginning on page 4 of this prospectus and under any similar headings in any amendment or supplement to this prospectus or in any filing with the Securities and Exchange Commission that is
incorporated by reference herein. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May 3, 2019
</B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_3">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_5">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_7">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_8">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom719612_9">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange
Commission, or SEC, using a &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer,&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended, or the Securities Act. Under this registration statement, the
selling stockholders may sell from time to time in one or more offerings the common stock described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the selling
stockholders have not, authorized anyone to provide you with information<B></B>&nbsp;other than the information contained or incorporated by reference in this prospectus and any related prospectus supplement. No one is making offers to sell or
seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus and any prospectus supplement is accurate only as of the date on the front of
this prospectus or the prospectus supplement, as applicable, and that any information incorporated by reference in this prospectus or any prospectus supplement is accurate only as of the date given in the document incorporated by reference,
regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References in this prospectus to &#147;ACADIA,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to ACADIA
Pharmaceuticals Inc., together with our wholly-owned subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ACADIA&#148; and &#147;NUPLAZID&#148; are our registered trademarks. Our logos
and trademarks are the property of ACADIA Pharmaceuticals Inc. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#146; trademarks, trade dress, or
products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere or incorporated by reference into this prospectus. Because it is a summary, it does not contain all
of the information that you should consider before investing in our securities. You should read this entire prospectus carefully, including the section entitled &#147;Risk Factors&#148;, any prospectus supplement and the documents that we
incorporate by reference into this prospectus, before making an investment decision.</I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous
system disorders. We have a portfolio of product opportunities led by our novel drug, NUPLAZID (pimavanserin), which was approved by the U.S. Food and Drug Administration, or FDA, in April 2016 for the treatment of hallucinations and delusions
associated with Parkinson&#146;s disease psychosis, or PD Psychosis. We hold worldwide commercialization rights to pimavanserin. We launched NUPLAZID in the United States in May 2016 with the recommended dosing of 34 mg once a day taken as two 17 mg
tablets. In June 2018, the FDA approved a 34 mg NUPLAZID capsule formulation and a 10&nbsp;mg NUPLAZID tablet and during the first quarter of 2019 we discontinued commercial sales of the 17 mg tablets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that pimavanserin has the potential to address important unmet medical needs in neurological and psychiatric disorders in addition to PD Psychosis
and we plan to continue to study the use of pimavanserin in multiple disease states. For example, we believe dementia-related psychosis, or DRP, represents one of our most important opportunities for further exploration. Following our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 Meeting with the FDA and agreement with the agency on our clinical development plan, we initiated our Phase 3 HARMONY relapse prevention study in the fourth
quarter of 2017, which allows us to evaluate pimavanserin for DRP, which includes psychosis in patients with Alzheimer&#146;s disease, dementia with Lewy bodies, Parkinson&#146;s disease dementia, vascular dementia and frontotemporal dementia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the National Institute of Mental Health, major depressive disorder, or MDD, affects approximately 16&nbsp;million adults in the United States,
with approximately 2.5&nbsp;million adults treated with adjunctive therapy. The majority of people who suffer from MDD do not respond adequately to initial antidepressant therapy. In October 2018, we announced positive
<FONT STYLE="white-space:nowrap">top-line</FONT> results from CLARITY, a Phase 2 study evaluating pimavanserin for adjunctive treatment in 207 patients with MDD who had a confirmed inadequate response to existing first-line, SSRI or SNRI,
antidepressant therapy. In the study, pimavanserin met the <FONT STYLE="white-space:nowrap">pre-specified</FONT> primary endpoint and key secondary endpoint demonstrating statistically significant improvement in the Hamilton <FONT
STYLE="white-space:nowrap">Depression-17</FONT> Rating Scale and the Sheehan Disability Scale, respectively, relative to placebo. Positive results were also observed in seven additional secondary endpoints including response rate, improvement in
sexual function, and a reduction in daytime sleepiness. Pimavanserin was generally well-tolerated in the study with no meaningful weight gain observed or impact on motor function. In February 2019, we conducted an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 Meeting with the FDA and in April 2019 we initiated our Phase 3 CLARITY program evaluating pimavanserin as an adjunctive treatment for major depressive disorder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also believe schizophrenia represents a disease with multiple unmet or <FONT STYLE="white-space:nowrap">ill-served</FONT> needs and we are currently
exploring the utility of pimavanserin in this area. In the fourth quarter of 2016, we initiated two studies evaluating the adjunctive use of pimavanserin in patients with schizophrenia. ENHANCE is a Phase 3 study evaluating pimavanserin for
adjunctive treatment of schizophrenia in patients with an inadequate response to their current antipsychotic therapy. ADVANCE is a Phase 2 study evaluating pimavanserin for adjunctive </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment in patients with negative symptoms of schizophrenia. Enrollment in both of these studies has been completed and we expect to report <FONT STYLE="white-space:nowrap">top-line</FONT>
results for the ENHANCE study in <FONT STYLE="white-space:nowrap">mid-2019</FONT> and for the ADVANCE study around the end of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, we
acquired an exclusive North American license to develop and commercialize trofinetide for Rett syndrome and other indications from Neuren Pharmaceuticals. Rett syndrome is a debilitating neurological disorder that occurs predominantly in females
following apparently normal development for the first six months of life. Typically, between six to eighteen months of age, patients experience a period of rapid decline with loss of purposeful hand use and spoken communication and inability to
independently conduct activities of daily living. Symptoms also include seizures, disorganized breathing patterns, scoliosis and sleep disturbances. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth
factor 1 <FONT STYLE="white-space:nowrap">IGF-1</FONT> designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Trofinetide has been granted FDA Fast Track Status and Orphan Drug
Designation in the U.S. and Europe. Currently, there are no approved medicines for the treatment of Rett syndrome. We plan to initiate a Phase 3 randomized, double-blind placebo-controlled study evaluating trofinetide in girls <FONT
STYLE="white-space:nowrap">5-20</FONT> years of age with Rett syndrome in the fourth quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in January 1997.
Our principal executive offices are located at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130, and our telephone number at that address is (858) <FONT STYLE="white-space:nowrap">558-2871.</FONT> Our website address is
www.acadia-pharm.com. The information contained in, or that can be accessed through, our website is not part of this prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Offered by the Selling Stockholders </P></TD>
<TD>40,203,111 shares<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market Symbol </P></TD>
<TD>ACAD </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 489,269 shares of common stock that may be issued upon the exercise of warrants held by certain of the
selling stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders named in this prospectus may offer and sell up to 40,203,111 shares of our common stock,
including 489,269 shares of our common stock issuable upon the exercise of warrants issued by us in a private placement that closed on December&nbsp;17, 2012. Throughout this prospectus, when we refer to the shares of our common stock being
registered on behalf of the selling stockholders, we are referring to all shares of common stock reported to us as owned by the selling stockholders as of April&nbsp;29, 2019, as well as the maximum number of shares that may be issued upon the
exercise of warrants held by the selling stockholders as of April&nbsp;29, 2019. We agreed to file the registration statement to which this prospectus forms a part to register these shares pursuant to a Registration Rights Agreement with the selling
stockholders dated January&nbsp;6, 2016. Additional information with respect to the Registration Rights Agreement is contained in this prospectus under the heading &#147;Selling Stockholders&#148; and in our current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;7, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to the selling stockholders in this prospectus, we are
referring to the entities named in this prospectus as the selling stockholders and, as applicable, any donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT>
selling shares received after the date of this prospectus from the selling stockholders as a gift, pledge, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related transfer. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should consider
carefully the specific risk factors discussed in the sections entitled &#147;Risk Factors&#148; contained in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2019, as filed with the
Securities and Exchange Commission, or SEC, which is incorporated in this prospectus by reference in its entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any prospectus
supplement hereto. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the
risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case, the
trading price of our common stock could decline and you might lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_3"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains, and the documents incorporated by reference herein and any applicable prospectus supplement may contain, forward-looking statements
within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future financial performance and involve
known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking
statements. Forward-looking statements may include, but are not limited to statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits to be derived from NUPLAZID (pimavanserin) and from our drug candidates, including trofinetide;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential market opportunities for pimavanserin and our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategy for the commercialization of NUPLAZID; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans for exploring and developing pimavanserin for indications other than Parkinson&#146;s disease psychosis
and trofinetide for Rett syndrome; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and timing with respect to seeking regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential commercialization of any of our drug candidates that receive regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing, results or implications of clinical trials and other development activities involving
NUPLAZID and our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our existing and potential future collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of future payments, revenues and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding our capital requirements, future expenses and need for additional financing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible changes in legislation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;could&#148;,
&#147;would&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;projects&#148;, &#147;predicts&#148;, &#147;potential&#148; and similar expressions (including their use in the
negative) intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading &#147;Risk Factors&#148; in our SEC filings, and may provide additional information in any applicable prospectus supplement. Also,
these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
should read this prospectus, the registration statement of which this prospectus is a part, the documents incorporated by reference herein, and any applicable prospectus supplement completely and with the understanding that our actual future results
may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking
statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of shares of our common stock by the selling stockholders pursuant to this prospectus. A portion of the
shares covered by this prospectus are issuable upon exercise of warrants to purchase our common stock. Upon any exercise of any of the warrants for cash, the applicable selling stockholder would pay us the exercise price set forth in the warrants.
The cash exercise price of the warrants to purchase up to 489,269 shares of our common stock issued on December&nbsp;17, 2012 is $0.01 per share. We expect to use any proceeds from the exercise of the warrants for cash primarily for our working
capital and other corporate and operational purposes. Under certain conditions set forth in the warrants, the warrants are exercisable on a cashless basis. If any of the warrants are exercised on a cashless basis, we would not receive any cash
payment from the applicable selling stockholder upon any such exercise of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each selling stockholder will pay any underwriting discounts and
commissions and any expenses incurred by the selling stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by such selling stockholder in disposing of shares covered by this prospectus, provided that we have
agreed to bear legal expenses of the selling stockholders of up to $50,000 per underwritten public offering of the shares offered by this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_5"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders named in this prospectus may offer and sell up to 40,203,111 shares of our common stock, including 489,269 shares of our common stock
issuable upon the exercise of warrants. The foregoing shares and warrants represent all shares of common stock reported to us as held by the selling stockholders as of April&nbsp;29, 2019 and the maximum number of shares of common stock issuable
upon the exercise of warrants held by the selling stockholders as of April&nbsp;29, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2016, in connection with a <FONT
STYLE="white-space:nowrap">follow-on</FONT> public offering of our common stock, we entered into a Registration Rights Agreement with the selling stockholders, pursuant to which we agreed that, if the selling stockholders demand that we register
their shares of our common stock for resale under the Securities Act, we would be obligated to effect such registration. Our registration obligations under this Registration Rights Agreement cover all shares of our common stock now held or later
acquired by the selling stockholders, will continue in effect for up to 10 years after the date of the Registration Rights Agreement, and include our obligation to facilitate certain underwritten public offerings of our common stock by the selling
stockholders in the future. We have agreed to bear all expenses incurred by us in effecting any registration pursuant to the Registration Rights Agreement as well as the legal expenses of the selling stockholders of up to $50,000 per underwritten
public offering effected pursuant to the Registration Rights Agreement. Additional information with respect to the Registration Rights Agreement is contained in our current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the
SEC on January&nbsp;7, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, or <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> and
Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP, or BBA, are each directors of ACADIA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the ownership of the shares of
common stock, the Registration Rights Agreement and Julian C. Baker&#146;s and Stephen R. Biggar&#146;s positions on our Board of Directors, the selling stockholders have not had any material relationship with us or our affiliates within the past
three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below, including the footnotes, lists the selling stockholders and other information regarding the beneficial ownership of the
shares of common stock held by each of the selling stockholders based on information provided to us by the selling stockholders. The percentages of shares owned prior to and after the offering are based on 144,127,644 shares of our common stock
outstanding as of March&nbsp;31, 2019, which includes the outstanding shares of common stock offered by this prospectus and the maximum number of shares of our common stock issuable upon exercise of the warrants in full for cash and the shares
reported to us as beneficially owned by the selling stockholders from options. The number of shares beneficially owned prior to the offering indicates the number of shares of common stock reported to us as beneficially owned by the selling
stockholders, as of April&nbsp;29, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum number of shares to be sold column indicates the total number of shares of our common stock,
including the shares of common stock issuable upon exercise of the warrants in full for cash, that the selling stockholders may offer under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares beneficially owned after offering number assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus,
including all of the shares of our common stock issuable upon exercise of the warrants. However, because the selling stockholders may sell all or some of their shares under this prospectus from time to time, or in another permitted manner, we cannot
assure you as to the actual number of shares that will be sold by the selling stockholders or that will be held by the selling stockholders after completion of any sales. We do not know how long any of the selling stockholders will hold the shares
before selling them. Information concerning the selling stockholders may change from time to time and changed information will be presented in a supplement to this prospectus if and when necessary and required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell all, some or none of their shares in this offering. See &#147;Plan of Distribution&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Shares&nbsp;Beneficially&nbsp;Owned&nbsp;&nbsp;<BR>Prior&nbsp;to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number&nbsp;of<BR>Shares&nbsp;to&nbsp;be<BR>Sold&nbsp;Pursuant<BR>to&nbsp;this<BR>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Shares&nbsp;Beneficially&nbsp;Owned&nbsp;&nbsp;<BR>After&nbsp;Offering&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP (2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,529,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,203,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of the outstanding shares of our common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The selling stockholders may offer and sell all or part of the common stock covered by this prospectus, but no
estimates can be made as to the amount of shares of common stock that will be held by the selling stockholders after the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under the terms of the warrants held by selling stockholders issued on December&nbsp;17, 2012, the number of
shares of our common stock that may be acquired by the selling stockholders upon any exercise of the warrants is generally limited to the extent necessary to ensure that, following such exercise, the total number of shares of our common stock then
beneficially owned by the selling stockholders, together with their affiliates and any other persons or entities whose beneficial ownership, as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the SEC,
would not exceed 19.99% of the total number of shares of our common stock then issued and outstanding. Solely for purposes of this table, the 19.99% limitation is disregarded, and the numbers of shares of common stock beneficially owned do not
reflect this limitation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock reported to us as beneficially owned by Baker Bros. Advisors LP are held by the
following selling stockholders (i) 667, L.P., or 667 (3,779,033 shares of common stock, including 42,131 shares of common stock issuable upon the exercise of warrants held by 667, without giving effect to the limitations on exercise described in
note (2)&nbsp;above) and (ii)&nbsp;Baker Brothers Life Sciences, L.P., or BBLS (36,424,078 shares of common stock, including 447,138 shares of common stock issuable upon the exercise of warrants held by BBLS, without giving effect to the limitations
on exercise described in note (2)&nbsp;above). In addition, (A)&nbsp;Julian C. Baker holds 73,216 shares of common stock, including 1,569 shares of common stock issuable upon the exercise of warrants held by Julian C. Baker, and options to acquire
57,500 shares of common stock, which are exercisable within 60 days of the date hereof, (B)&nbsp;Stephen R. Biggar holds options to acquire 96,500 shares of common stock, which are exercisable within 60 days of the date hereof, (C)&nbsp;Felix J.
Baker holds 73,216 shares of common stock, including 1,569 shares of common stock issuable upon the exercise of warrants held by Felix J. Baker, and (D)&nbsp;FBB3 LLC, or FBB3, holds 25,985 shares of common stock, including 557 shares of common
stock issuable upon the exercise of warrants held by FBB3. The shares of common stock held by FBB3 were contributed to FBB3 by Stephen R. Biggar. Julian C. Baker and Felix J. Baker are the sole managers of FBB3 and by policy they do not transact in
or vote the securities of ACADIA held by FBB3. BBA is the management company and investment adviser to 667 and BBLS and may be deemed to beneficially own all shares held by 667, BBLS, Julian C. Baker, Stephen R. Biggar, Felix J. Baker and FBB3.
Baker Bros. Advisors (GP) LLC, or <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> is the sole general partner of BBA. Julian C. Baker and Felix J. Baker have voting and investment power over the shares held by each of 667 and BBLS, as managing
members of <FONT STYLE="white-space:nowrap">BBA-GP.</FONT> Julian C. Baker, Felix J. Baker, BBA and <FONT STYLE="white-space:nowrap">BBA-GP</FONT> disclaim beneficial ownership of all shares held by 667 and BBLS, except to the extent of their
indirect pecuniary interest therein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell the shares offered by this prospectus. The selling stockholders, including their donees, pledgees, transferees or other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or
other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in
private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. To the
extent any of the selling stockholders gift, pledge, grant a security interest in, or otherwise transfer the shares offered hereby, such transferees may offer and sell the shares from time to time under this prospectus, provided that this prospectus
has been amended under Rule 424(b)(3) or other applicable provision of the Securities Act to include the name of such transferee in the list of selling stockholders under this prospectus if and when necessary or required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. They may use any one or
more of the following methods when disposing of shares or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which a broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account under this prospectus;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; or through market makers or into an existing market for the shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales entered into after the effective date of the registration statement of which this prospectus is a
part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise, after the effective date of the registration statement of which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the distribution of the common stock by any selling stockholders to its partners, members or
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through broker-dealers that agree with the selling stockholders to sell a specified number of such shares at a
stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwritten offerings on a firm commitment or best efforts basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the shares, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more
derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as
supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the shares offered by them will be the
purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of
common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. We will, however, receive the proceeds of any warrants exercised for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,
provided that they meet the criteria and conform to the requirements of that rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker-dealers that act in connection
with the sale of securities may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act in connection with such sales, and any commissions received by such broker-dealers and any profit on the resale
of the securities sold by them while acting as principals may be deemed to be underwriting discounts or commissions under the Securities Act. In the event that any selling stockholder is deemed to be an &#147;underwriter&#148; within the meaning of
Section&nbsp;2(11) of the Securities Act, the selling stockholder will be subject to the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the
sale of the shares against certain liabilities, including liabilities arising under the Securities Act. To our knowledge and based upon information we received from the selling stockholders, each selling stockholder that is affiliated with a
broker-dealer acquired the shares of common stock being registered hereunder in the ordinary course of business, and, at the time such selling stockholder acquired the shares being registered hereunder, such selling stockholder did not have any
agreement or understanding, directly or indirectly, with any person to distribute such shares. To our knowledge, none of the selling stockholders received any shares as underwriting compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the
registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To comply with the securities laws of some states, if applicable, the shares may be sold in these
jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is
available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may
apply to sales of shares of our common stock in the market and to the activities of the selling stockholders and their affiliates. These rules may limit the timing of purchases and sales of the shares by such selling stockholders. Regulation M may
also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares of
common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will bear all
of the costs, expenses and fees in connection with the registration of the shares of common stock, other than any commissions, discounts or other fees payable to underwriters or broker-dealers in connection with any sale of shares, which will be
borne by the selling stockholder selling such shares of common stock. We have agreed to bear legal expenses of the selling stockholders of up to $50,000 per underwritten public offering of the shares offered by this prospectus. We have agreed to
indemnify the selling stockholders against certain liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement,
of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered by this prospectus will be passed upon for us by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements (and schedule) included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2018, as set forth in their reports, which
are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements (and schedule) are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom719612_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a reporting company and we file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC
a registration statement under the Securities Act with respect to the common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement or the exhibits which are part of the registration statement. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and the exhibits filed as part of the
registration statement. Our SEC filings are available to the public from the SEC&#146;s website at www.sec.gov. We maintain a website at www.acadia-pharm.com. The information contained in, or that can be accessed through, our website is not part of
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important information to you by
referring to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the following documents we filed with the SEC pursuant to Section&nbsp;13 of the Exchange Act and any future filings we will make
with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this prospectus until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item 2.02 or Item
7.01 of Form <FONT STYLE="white-space:nowrap">8-K):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000156459019004596/acad-10k_20181231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000156459019004596/acad-10k_20181231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2018 from our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312519129723/d664711ddef14a.htm">Schedule 14A</A>
(other than information furnished rather than filed) filed with the SEC on April&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000156459019014909/acad-10q_20190331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarter ended March&nbsp;31, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312519064601/d681058d8k.htm">March
<U></U>&nbsp;6, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312519094603/d729060d8k.htm">April<U></U>&nbsp;1, 2019</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312504091609/d8a12g.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> dated May&nbsp;19, 2004. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may access our annual report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> Proxy Statement, and amendments, if any, to those documents filed or
furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at the SEC&#146;s website or our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC.
The reference to our website does not constitute incorporation by reference of the information contained in our website. We do not consider information contained on, or that can be accessed through, our website to be part of this prospectus or the
related registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of our SEC filings at no cost, by telephoning or writing us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ACADIA
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3611 Valley Centre Drive, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(858) <FONT
STYLE="white-space:nowrap">558-2871</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the costs and expenses, payable by us in connection with the offering of common stock being registered. All amounts are
estimates except the registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;to<BR>Be Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the Delaware General Corporation Law allows a corporation to eliminate the personal liability of directors of a corporation to the
corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law,
authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the
corporation and certain other persons serving at the request of the corporation in related capacities against amounts paid and expenses incurred in connection with an action or proceeding to which he is or is threatened to be made a party by reason
of such position, if such person shall have acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interest of the corporation, and, in any criminal proceeding, if such person had no reasonable cause to
believe his conduct was unlawful; provided that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the adjudicating court determines that such indemnification is proper under the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation and bylaws include provisions that indemnify our directors and officers for actions taken in such capacity, if the actions were taken in good faith and in a manner reasonably believed to be in our best
interests and, in a criminal proceeding, the director or officer had no reasonable cause to believe that his or her conduct was unlawful. A director or officer who is successful in defending a claim will&nbsp;be indemnified for all expenses incurred
in connection with his or her defense. We have entered into indemnification agreements with our officers and directors that require us to indemnify such persons against any and all expenses (including attorneys&#146; fees), witness fees, damages,
judgments, fines, settlements and other amounts incurred in connection with any action, suit or proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was or at any time
becomes a director, an officer or an employee of ACADIA or any of our affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with
respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain directors and officers insurance
providing indemnification for certain of our directors, officers, affiliates, partners and employees for certain liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312515281018/d937801dex31.htm">Amended and Restated Certificate of Incorporation, as Amended (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Quarterly Report
 on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> filed August<U></U>&nbsp;6, 2015).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000141588913001809/acadiaexhibit.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed September<U></U>&nbsp;12, 2013).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits <A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312515281018/d937801dex31.htm">3.1</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000141588913001809/acadiaexhibit.htm">3.2</A> above.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000091205700054458/a2033472zex-4_1.txt">Form of common stock certificate of the Registrant (incorporated by reference to Exhibit 4.1 to Registration Statement No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;333-52492).</FONT></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000156459019004596/acad-ex42_574.htm">Form of Amended and Restated Warrant to Purchase Common Stock (superseding the form of warrant issued to certain purchasers in a private placement
 on December<U></U>&nbsp;17, 2012) (incorporated by reference to Exhibit 4.2 to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> filed February<U></U>&nbsp;27, 2019).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1070494/000119312516423572/d101334dex41.htm">Registration Rights Agreement, dated January<U></U>&nbsp;
6, 2016, between the Registrant and the investors listed on Schedule A thereto (incorporated by reference to Exhibit 4.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed January<U></U>&nbsp;7,
2016).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d719612dex51.htm">Opinion of Counsel. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d719612dex231.htm">Consent of Independent Registered Public Accounting Firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d719612dex51.htm">Consent of Counsel (included in Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#ii719612_100">Power of Attorney (included on signature page) </A></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the
effective registration statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however,</I> that
subparagraphs (i), (ii) and (iii)&nbsp;above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s
annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the provisions of Item 15 above, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ii719612_100"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 3, 2019.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACADIA PHARMACEUTICALS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;/s/ Stephen R. Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen R. Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen R.
Davis and Austin D. Kim, and each of them, as his or her true and lawful attorneys in fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign
any and all amendments to this registration statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys in fact and agents full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that
said attorneys in fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Stephen R. Davis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen R. Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer, Director<BR><I>(Principal Executive
Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Elena Ridloff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Elena Ridloff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Executive Vice President, Chief Financial Officer<BR><I>(Principal
Financial Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Eric Miller</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Eric Miller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Director and Controller<BR><I>(Principal Accounting
Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Stephen R. Biggar</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen R. Biggar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairman of the Board</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Julian Baker</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Julian Baker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Laura Brege</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Laura Brege</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ James Daly</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James Daly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Edmund Harrigan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Edmund Harrigan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Daniel Soland</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Daniel Soland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 3, 2019</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d719612dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g719612g13e51.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g719612g40e54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">May&nbsp;3, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">ACADIA
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">3611 Valley Centre Drive, Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego, CA 92130
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">You have requested our
opinion, as counsel to ACADIA Pharmaceuticals Inc., a Delaware corporation (the &#147;<B></B><B><I>Company</I></B><B></B>&#148;), with respect to certain matters in connection with the filing by the Company of a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (the &#147;<B></B><B><I>Registration Statement</I></B><B></B>&#148;) with the Securities and Exchange Commission, including a related prospectus filed with the Registration Statement (the
&#147;<B></B><B><I>Prospectus</I></B><B></B>&#148;), covering the registration for resale of up to 40,203,111 shares of the Common Stock, $0.0001 par value, of the Company on behalf of certain selling stockholders, including 39,713,842 currently
outstanding shares of Common Stock (the &#147;Shares&#148;) and up to 489,269 shares of Common Stock (the &#147;<B></B><B><I>Warrant Shares</I></B><B></B>&#148;) issuable upon the exercise of certain warrants held by such selling stockholders (the
&#147;<B></B><B><I>Warrants</I></B><B></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In connection with this opinion, we have examined and relied upon the Registration Statement,
the Prospectus, the Warrants, the Company&#146;s Amended and Restated Certificate of Incorporation, as amended, its Amended and Restated Bylaws, and the originals or copies certified to our satisfaction of such records, documents, certificates,
memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to
originals of all documents submitted to us as copies thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently sought to verify such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Our opinion is expressed only with respect to the federal laws of the United States of America and the General Corporation Law of the State of Delaware.
We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">On the basis of the foregoing, and in reliance thereon, we are of the opinion that (i)&nbsp;the Shares have been validly issued and are fully paid and
nonassessable, and (ii)&nbsp;the Warrant Shares, when issued and sold in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g719612g19b29.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g719612g13e51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus and to the
filing of this opinion as an exhibit to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cooley LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sean M. Clayton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sean M. Clayton</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g719612g19b29.jpg" ALT="LOGO">
 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d719612dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; in this Registration Statement (Form
<FONT STYLE="white-space:nowrap">S-3)</FONT> and related Prospectus of ACADIA Pharmaceuticals Inc. for the registration of shares of its common stock and to the incorporation by reference therein of our reports dated&nbsp;February 26, 2019, with
respect to the consolidated financial statements and schedule of ACADIA Pharmaceuticals Inc.,&nbsp;and the effectiveness of internal control over financial reporting of ACADIA Pharmaceuticals Inc., included in its Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2018, filed with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;3, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g719612g13e51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g719612g13e51.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M+%,S"@ H * "@ H S=<UNT\/Z5)?W;'8O"J.KMV45,Y*"NSJPF%J8JJJ5/\
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M!>+F.!MZ@] YX0?@!^@KDI+GFY,^NS2I' X*.%I[O3Y=?O9ZU78?'!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % #9(TE0I(BNAZJPR#0--Q=T-A@AMU*PQ)
6$I.2$4 ?I22ML.4Y3=Y.Y)3)"@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g719612g19b29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g719612g19b29.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MK,).N&*@@>C8]^M &?<^&]5U&.\N;B.QMKN[$N^*"5F0$P&)27V L>F3M&
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
>H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g719612g40e54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g719612g40e54.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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,83G)'H3DY^IH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g719612g97y90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g719612g97y90.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( +0
M? ,!$0 "$0$#$0'_Q  =  $  @(# 0$             " D'"@4&"P0#_\0
M21    8" 0$$ PL'" L      @,$!08' 0@ "0H1$A,4%1<6(38Y56%U>)6T
MU"(Q,E&!MK<C)"DS04)Q=Q@9)B<W4W."H:+!_\0 '@$!  $$ P$!
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M7+3A$X1.$5HG2HZ=<JZ@.P;:S.*%R;J#KM8VO]VS(D)J<O#1@[)R*!LB_&,
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MK5;T!:#AH2'-1&W)>E02%4V44I&G(4C 8M/L81@ &JE_B"5S!,7$<6N^H_\
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M;5:'9M?FIL?&9:G<FAY;T3LU.*4>#4J]M<4Q:Q"M3&8]XQ.J2G%'DCQ[PRS
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M$<<4C(*D!I:XXXM(QQ/'.>?R=6/,N:UIO?<*35[MY6$KN6KI--=5]YEM$/\
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%N?%?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
